# Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder

> **NCT01466205** · PHASE2 · UNKNOWN · sponsor: **Larry J. Siever** · enrollment: 20 (estimated)

## Conditions studied

- Cognitive Impairments
- Schizotypal Personality Disorder

## Interventions

- **DRUG:** DAR-0100A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01466205
- **Lead sponsor:** Larry J. Siever
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-01
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2012-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01466205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01466205, "Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01466205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*